The mission of the Penn ADCC is to increase research and education on AD, related dementias, normal brain aging and mild cognitive impairment (MCI), as well as support development of better diagnostics and preventions/treatments for AD and related disorders. The Penn ADCC provides research training, stimulates new research on normal aging and neurodegenerative dementias as well as development of novel techniques to address the challenges of conducting research on these disorders. The Penn ADCC is a highly interdisciplinary and seamlessly integrated Center with 5 Cores that collaborate extensively with other investigators at and beyond Penn, including the NIH/NIA funded AD Centers (ADCs), NACC, AD Cooperative Study (ADCS), AD Education and Referral (ADEAR) Center, the AD Neuroimaging Initiative (ADNI), AD Genetics Consortium (ADGC) and other NIH/public/private initiatives on AD, related disorders and healthy brain aging.
The Aims of the Penn ADCC are implemented through: 1) Administrative Core A to oversee and direct the activities of the ADCC;2) Clinical Core B to recruit, follow and study subjects with AD, MCI or related disorders and controls;3) Data Management and Biostatistics Core C to provide data management and biostatistical expertise;4) Neuropathology, Genetics and Biomarker Core D to establish postmortem diagnoses on ADCC subjects, and bank CNS tissues, DNA and biofluids from ADCC subjects for diagnostic studies and research;5) Education, Recruitment and Retention Core E to develop, implement and monitor recruitment and retention programs and ensure that the ADCC team as well as patients and families have up to- date knowledge of AD and related diseases;6) Pilot Grant Program to stimulate novel research on AD and related disorders;7) Collaborations with other investigators at and beyond Penn to improve diagnostics and treatments for AD and related disorders as well as increase understanding of these conditions and promote healthy brain aging. In summary, the Penn ADCC contributes to US and global strategies to meet the worldwide challenges of rapidly aging populations and the epidemic of AD and related disorders. In alignment with NIA RFA-AG-11- 005, the Penn ADCC accomplishes its mission in the renewal period through research on AD and related disorders as well as normal aging and through education to increase understanding of these disorders and their global effects.

Public Health Relevance

of the Penn ADCC is that it challenges/re-defines current clinical practice paradigms and research on AD and related disorders as well as MCI and normal aging by utilizing novel concepts and approaches to achieve the goals of this ADCC which are to increase research and education on AD, related dementias, normal brain aging and MCI, as well as support development of better diagnostics and preventions/treatments for AD and related disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG010124-23
Application #
8501176
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5 (M2))
Program Officer
Silverberg, Nina B
Project Start
1997-07-15
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
23
Fiscal Year
2013
Total Cost
$1,358,461
Indirect Cost
$509,423
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Jansen, Willemijn J; Ossenkoppele, Rik; Tijms, Betty M et al. (2018) Association of Cerebral Amyloid-? Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry 75:84-95
Goldman, Jennifer G; Andrews, Howard; Amara, Amy et al. (2018) Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Mov Disord 33:282-288
Seo, Sang Won; Thibodeau, Marie-Pierre; Perry, David C et al. (2018) Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration. Neurology 90:e1047-e1056
Shi, Min; Tang, Lu; Toledo, Jon B et al. (2018) Cerebrospinal fluid ?-synuclein contributes to the differential diagnosis of Alzheimer's disease. Alzheimers Dement 14:1052-1062
Stites, Shana D; Rubright, Jonathan D; Karlawish, Jason (2018) What features of stigma do the public most commonly attribute to Alzheimer's disease dementia? Results of a survey of the U.S. general public. Alzheimers Dement 14:925-932
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Kovacs, Gabor G; Kwong, Linda K; Grossman, Murray et al. (2018) Tauopathy with hippocampal 4-repeat tau immunoreactive spherical inclusions: a report of three cases. Brain Pathol 28:274-283

Showing the most recent 10 out of 720 publications